Enanta Pharmaceuticals Stock News

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver disease

ENTA earnings call for the period ending June 30, 2022.

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -12.50% and 3.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA ) Q3 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Jennifer Viera - Senior Director, IR & Corporate Communications Jay Luly - P

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -12.50% and 3.92%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

MediWound (MDWD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 5 7 0 0

Enanta Pharmaceuticals (ENTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Upgrades According to Wells Fargo, the prior rating for Rocket Companies Inc (NYSE:RKT) was changed from Equal-Weight to Overweight. In the first quarter, Rocket Companies showed an EPS of $0.15, comp

The World Health Organization said COVID cases were lower overall in the week through June 19, but moved higher in Southeast Asia, the Eastern Mediterranean and the European regions as the BA.4 and BA

Enanta Pharmaceuticals (ENTA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be m

The biotech is seeking compensation.

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases

Enanta Pharmaceuticals (NASDAQ:ENTA) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 4 4 0 0

Upgrades Citigroup upgraded the previous rating for FinVolution Group (NYSE:FINV) from Neutral to Buy. FinVolution Gr earned $0.30 in the first quarter, compared to $0.31 in the year-ago quarter. The